Research programme: skin disorder therapeutics - Crescita Therapeutics
Alternative Names: CTX 103 - Crescita TherapeuticsLatest Information Update: 19 Jun 2020
At a glance
- Originator Nuvo Research
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders